Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
Key Highlights
- ➤Rezdiffra net sales reached $431.3 million, up 50% year-over-year
- ➤Madrigal posted $55.4 million net income versus $114.2 million loss
- ➤Rezdiffra year-to-date net sales hit $1.1 billion, achieving blockbuster status
- ➤MAESTRO-CSPH Phase 3 trial expected to enroll more than 2,000 F4c patients
- ➤U.S. F2-F3 MASH addressable market exceeds 530,000 patients through June 30, 2026
Expert Statements
Bill Sibold, Chief Executive Officer of Madrigal Pharmaceuticals
“Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening prescriber adoption and accelerating market growth. Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch, and we are still early in a rapidly growing market. Our latest analysis shows the addressable U.S. F2-F3 market is on track to increase more than 30 percent by year-end 2026, reinforcing how quickly this category is developing and the significant runway ahead.”
Bill Sibold, Chief Executive Officer of Madrigal Pharmaceuticals
“Madrigal’s next major opportunity is in well-compensated cirrhosis, or F4c, an urgent unmet need for patients. Our objective in F4c is clear: be first and best. Our ongoing MAESTRO-NASH OUTCOMES trial positions us to deliver the first approved therapy to patients with this advanced stage of MASH. MAESTRO-CSPH is our new, Phase 3, practice-shaping trial that we expect will extend our competitive advantage and strengthen our long-term leadership in this rapidly growing market.”
* Third-quarter 2026 Rezdiffra(®) (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability * Rezdiffra reaches a major milestone, achieving blockbuster status with year-to-date net sales of $1.1 billion * As of Sept. 30, 2026, more than 55,850 patients on Rezdiffra, nearly doubling from 3Q25, reflecting continued strong prescriber adoption and high patient demand * U.S. F2-F3 MASH market is accelerating, growing to more than 530,000 addressable patients through June 30, 2026, on track for more than 30% growth by YE26 * Madrigal strengthens its leadership position in well-compensated MASH cirrhosis (F4c) with new MAESTRO-CSPH outcomes clinical trial; MAESTRO NASH OUTCOMES on track, data expected late 2027 * Reports cash, cash equivalents, restricted cash and marketable securities of $961.8 million as of Sept. 30, 2026 * Appointed John C. Reed, M.D., Ph.D., to Board of Directors * Company to host conference call today, Nov. 3, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2026 financial results and provides corporate updates.
Get started
Create a free account to read the full story.